ANLN Monoclonal antibody

• Featured Product
• KD/KO Validated

ANLN Monoclonal Antibody for WB, ELISA

Host / Isotype

Mouse / IgG1

Reactivity

human, mouse, rat

Applications

WB, IHC, ELISA

Conjugate

Unconjugated

Publications

5

CloneNo.

1B4A8

Cat no : 66643-1-Ig

Synonyms

Anillin, Scraps, scra, anillin, actin binding protein, Actin binding protein anillin

---

Validation Data Gallery

• 

  WB analysis using 66643-1-Ig

  Various lysates were subjected to SDS PAGE followed by western blot with 66643-1-Ig (ANLN antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of MCF-7 using 66643-1-Ig

  WB result of ANLN antibody (66643-1-Ig; 1:3000; incubated at room temperature for 1.5 hours) with sh-Control and sh-ANLN transfected MCF-7 cells.

• 

  WB analysis of rat brain using 66643-1-Ig

  rat brain tissue were subjected to SDS PAGE followed by western blot with 66643-1-Ig (ANLN antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of mouse brain using 66643-1-Ig

  mouse brain tissue were subjected to SDS PAGE followed by western blot with 66643-1-Ig (ANLN antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.

---

Tested Applications

• Positive WB detected in: HeLa cells, MCF-7 cells, rat brain tissue, mouse brain tissue, HEK-293 cells, U-251 cells, PC-12 cells

Recommended dilution

• Western Blot (WB): WB : 1:2000-1:10000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Published Applications

• KD/KO: See 1 publications below
• WB: See 5 publications below
• IHC: See 1 publications below

Product Information

66643-1-Ig targets ANLN in WB, IHC, ELISA applications and shows reactivity with human, mouse, rat samples.

• Tested Reactivity: human, mouse, rat
• Cited Reactivity: human, mouse
• Host / Isotype: Mouse / IgG1
• Class: Monoclonal
• Type: Antibody
• Immunogen: ANLN fusion protein Ag19294
• Full Name: anillin, actin binding protein
• Calculated Molecular Weight: 1124 aa, 124 kDa
• Observed Molecular Weight: 110 kDa~120 kDa
• GenBank Accession Number: BC034692
• Gene Symbol: ANLN
• Gene ID (NCBI): 54443
• RRID: AB_2815000
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Protein G purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Anillin, an actin-binding protein, is a conserved cleavage furrow component important for cytokinesis. The human anillin protein localizes to the nucleus during interphase, the cortex following nuclear envelope breakdown, and the cleavage furrow during cytokinesis. It interactions with at least two other furrow proteins, actin and the septins through its C-terminal PH domain and N-terminal actin-binding domain. In anillin knockdown cells, the cleavage furrow ingressed but failed to complete the ingression. Anillin has been found to be overexpressed in tumors and may serve as promising marker for pancreatic carcinoma molecular diagnostics as well as a prognostic indicator for non-small cell lung cancers.

Publications

Species	Application	Title
human,mouse	WB,IHC	Cancers (Basel); ANLN Promotes the Proliferation and Migration of Gallbladder Cancer Cells via STRA6-Mediated Activation of PI3K/AKT Signaling; Authors - Xiang Zhu ; KD Validated
human	WB	Cell Cycle; CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma.; Authors - Ling Li
human	WB	Clin Exp Pharmacol Physiol; PMID: 32198770; Authors - Min Zhang
human	WB	Front Genet; ANLN and KDR Are Jointly Prognostic of Breast Cancer Survival and Can Be Modulated for Triple Negative Breast Cancer Control.; Authors - Xiaofeng Dai
human	WB	Pathol Res Pract; Vasculogenic mimicry-associated novel gene signature predicted prognosis and response to immunotherapy in lung adenocarcinoma; Authors - Lei Zhang